Given that recent clinical studies have suggested that p53 mutations may be present in ~10% of newly diagnosed cases,3, 4, 5, 12 there is a great need to identify targeted therapies that do not include genotoxic-based modalities for CLL patients. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.